Clinical trial · Interventional
Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer
Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer: A Pilot, Randomized, Open Label, Controlled Study.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Organizational safety isues
Summary
Brief summary (as posted)
chlorpromazine displays a series of remarkable bio-molecular effects in cancer cells, as inhibition of cell growth, nuclear aberrations, inhibition of the phosphoinositide 3-kinase/mammilian target of rapamycin (PI3K/mTOR) axis, induction of cytotoxic autophagy, inhibition of glutamate and DRD2 receptors. This study will evaluate the addition of chlorpromazine to the first-line therapeutic protocol in colon cancer stage III.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Cancer Stage III | Malignant Colon Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ChlorproMAZINE 50 MG | Drug | — | UNRESOLVED |
| Control | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Control
- interventionNames
- Drug: Control
- type
- EXPERIMENTAL
- label
- Chloropromazine
- interventionNames
- Drug: ChlorproMAZINE 50 MG
Primary outcomes (1)
- measure
- Disease-free survival
- timeFrame
- one year
- description
- Disease-free survival as measured by Logrank
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Patients age ≥18 years old. * Patients with histologically confirmed surgically resected stage III colon cancer * No rectal cancer * Stage III disease (any pT, N1-2, M0) * Patients should have a good performance status according to Eastern Cooperative Oncology Group (ECOG) score (ECOG 0-2). * Patients with normal organic function as defined for the following criteria: * Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 times the upper normal limit of the local laboratory (LSN-LL); * Total serum bilirubin ≤ 2.0 x ULN-LL; * Absolute neutrophil count ≥ 1,500 / mm3; * Platelet count ≥ 100,000 / mm3; * Hemoglobin ≥ 8.0 g / dl; * Serum creatinine ≤ 1.5 x ULN-LL * Patients should undergone curative-intent complete surgical resection * Patients have at least one month from any major surgery to start of intervention * Written informed consent before enrollment Exclusion Criteria: * Patients with concurrent other malignancy or history of other malignancy treated within the past 3 years (other than non-melanoma skin cancer or in-situ cervical cancer) * Patients with metastatic disease * Patients who scheduled to receive any form of further adjuvant cancer therapy (A malignancy currently under active therapy * Pregnant or breast-feeding patients * Patients with known hypersensitivity or intolerance to CPZ * Patients with serious illness or psychiatric condition. * Patients have current participation in other protocols with experimental drugs. * Patients with no ability to ingest food orally. * Patients who have familial adenomatous polyposis, hereditary non-polyposis rectal cancer, or inflammatory bowel disease * Patients who are taken other chemoprevention drugs (ex. NSAIDs, Aspirin)
References
Publications (0)
Data not yet available